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le under thAbstract Introduction: Campylobacteriosis is one of the leading causes of gastro-
enteritis worldwide. This study describes the epidemiology of laboratory-confirmed
Campylobacter diarrheal infections in two facility-based surveillance sites in Guate-
mala.
Methods: Clinical, epidemiologic, and laboratory data were collected on patients
presenting with acute diarrhea from select healthcare facilities in the departments
of Santa Rosa and Quetzaltenango, Guatemala, from January 2008 through August
2012. Stool specimens were cultured for Campylobacter and antimicrobial suscepti-
bility testing was performed on a subset of isolates. Multidrug resistance (MDR) was
defined as resistance to P3 antimicrobial classes.
Results: Campylobacter was isolated from 306 (6.0%) of 5137 stool specimens col-
lected. For children <5 years of age, annual incidence was as high as 1288.8 per
100,000 children in Santa Rosa and 185.5 per 100,000 children in Quetzaltenango.hed by Elsevier Ltd. on behalf of Ministry of Health, Saudi Arabia.
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52 S.R. Benoit et al.Among 224 ambulatory care patients with Campylobacter, 169 (75.5%) received
metronidazole or trimethoprim-sulfamethoxazole, and 152 (66.7%) received or were
prescribed oral rehydration therapy. Antimicrobial susceptibilities were tested in 96
isolates; 57 (59.4%) were resistant to ciprofloxacin and 12 (12.5%) were MDR.
Conclusion: Campylobacter was a major cause of diarrhea in children in two
departments in Guatemala; antimicrobial resistance was high, and treatment
regimens in the ambulatory setting which included metronidazole and trimethoprim-
sulfamethoxazole and lacked oral rehydration were sub-optimal.
Published by Elsevier Ltd. on behalf of Ministry of Health, Saudi Arabia. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Campylobacteriosis, usually acquired by the con-
sumption and handling of poultry – is one of the
leading causes of gastroenteritis worldwide [1].
The illness is characterized by diarrhea, abdominal
cramps, and fever [2]. Although mortality is rare,
significant post-infectious sequelae such as Guil-
lain–Barre´ syndrome, irritable bowel syndrome,
and reactive arthritis do occur [3–6]. The utiliza-
tion of fluoroquinolones in feed animals to treat ill-
ness and promote growth has contributed to
increasingly quinolone-resistant Campylobacter
strains [7,8], complicating the treatment for pa-
tients with severe disease and immunocompro-
mised states, especially children [1].
In Guatemala, diarrhea is the second most com-
mon cause of morbidity and mortality in children
<5 years of age [9]. Small, community-based stud-
ies in Guatemala suggest that Campylobacter is a
common cause of diarrhea in children [10,11].
However, no estimates have been generated for
the incidence of campylobacteriosis in Guatemala
or for the degree of antimicrobial resistance.
Identification of Campylobacter requires specific
culturing techniques with micro-aerobic environ-
ments [12], and few laboratories in Guatemala rou-
tinely culture for this pathogen.
In this report, cases are characterized and the
incidenceof laboratory-confirmedcampylobacteriosis
is estimated from a facility-based surveillance sys-
tem in Guatemala from 2008 through 2012.
2. Methods
2.1. Study sites
In July 2007, the U.S. Centers for Disease Control
and Preventions (CDC) International Emerging
Infections Program (IEIP) in Guatemala, in collabo-
ration with the Ministry of Public Health and Wel-
fare (MSPAS) and the Universidad del Valle de
Guatemala (UVG), initiated a facility-based surveil-
lance system in the department of Santa Rosa.
Additional sites in the department of Quetzalten-ango were added in February of 2009. The surveil-
lance system captures patients of all ages in both
ambulatory and hospital settings, and diarrhea is
one of the syndromes under surveillance.
Santa Rosa, with a population of 346,590 per-
sons, is one of 22 administrative departments in
Guatemala, and it is located in the semi-tropical
southern part of the country. Ethnically, the popu-
lation is 15% Amerindian indigenous [13]. Quetzal-
tenango, with a population of 789,358 persons, is
in the western highlands and has a population that
is 62% Amerindian indigenous. Government health
facilities include hospitals, health centers staffed
by a physician and nurses, and health posts staffed
by nurses. In both surveillance sites, the facility-
based system includes a hospital and an ambulatory
component. In Santa Rosa, the surveillance system
includes the regional hospital in Cuilapa, the muni-
cipal capital of Santa Rosa, as well as the health
center and five health posts of the municipality
of Nueva Santa Rosa, located 30 km north of Cuila-
pa. In Quetzaltenango, surveillance includes the
regional hospital in the capital of Quetzaltenango,
as well as the three health centers and one health
post in the municipalities around the capital. In
this analysis, the health centers and health posts
were collectively considered ambulatory care facil-
ities, and cases captured in these facilities were
used for ambulatory surveillance. Data were in-
cluded from Santa Rosa between January 2008
and August 2012, and from Quetzaltenango be-
tween February 2009 and August 2012.2.2. Case detection and data collection
A case of diarrhea was defined asP3 loose or liquid
stools in a 24-h period with onset within the seven
days preceding presentation to any participating
facility by a patient residing in a municipality
covered by the surveillance system. To avoid
enrolling patients with chronic diarrhea, subjects
were excluded if they had any signs or symptoms
of diarrhea within the seven days prior to the onset
of the current illness. Surveillance nurses screened
patients by reviewing log book entries and
Burden of laboratory-confirmed Campylobacter infections 53assessing chief complaints for diarrhea-related vis-
its and admissions. These patients were inter-
viewed, and if found to meet the case definition,
detailed clinical, epidemiologic, demographic,
and socioeconomic data were obtained through
structured patient interviews and medical chart
abstractions [14]. In the ambulatory setting, facil-
ities were staffed with surveillance nurses during
all working hours and all patients presenting with
diarrhea were screened for eligibility. In the hospi-
tal setting, except for holidays, surveillance nurses
were on-duty seven days per week from 8:00 AM to
5:00 PM. Only patients who were admitted to the
hospital were screened for eligibility. This insured
that only severe cases of diarrhea were enrolled
in hospital surveillance, and it also was the only
feasible approach since surveillance nurses were
not able to collect all the necessary laboratory
and epidemiologic data from patients in the emer-
gency department (ED) before they were
discharged.
2.3. Laboratory methods
A stool specimen was requested of all consenting
patients. For children <5 years of age who were
unable to produce a specimen, a rectal swab was
collected and placed in Cary-Blair transport media.
Stool samples from the ambulatory facilities were
stored in Cary-Blair transport media in an insulated
cooler at 4 C, and transported within 24 h to one
of the two regional hospitals for initial processing
and testing. Samples were streaked by direct plat-
ing onto Campylobacter selective agar base, Kar-
mali (Oxoid, Basingstoke, UK) and incubated at
42 C for 48 h under microaerophilic conditions
provided by the CampyGenTM Generating System
(Oxoid, Basingstoke, UK). Small, gray, moist, and
flat spreading colonies were considered suspicious
of Campylobacter, and were placed on a stained
slide for microscopic examination. On visual exam-
ination, colonies with ‘‘gull-winged,’’ spiral, or
‘‘S’’-shaped structures were considered micro-
scopically suspect colonies, and were subsequently
plated on Mueller Hinton (Oxoid, Basingstoke, UK)
or blood agar and tested with oxidase and catalase
and the Dryspot Campylobacter test kit (Oxoid,
Basingstoke, UK) to confirm Campylobacter. The
hippurate test was used to identify C. jejuni [15].
A specimen was considered negative for Campylo-
bacter if no suspicious colonies grew after 72 h of
incubation. Isolates were sent to UVG laboratories
for Campylobacter and C. jejuni confirmation and
antimicrobial susceptibility testing. Due to limited
supplies, antimicrobial susceptibility testing was
performed on all cultures done from 2010 to 2011that grew Campylobacter, using minimum inhibi-
tory concentrations (MIC) via Etest (Biome´rieux,
Marcy lEtoile, France) for the following antimicro-
bial agents: nalidixic acid (NA), chloramphenicol,
ciprofloxacin, erythromycin, and tetracycline
[16]. Multidrug-resistance (MDR) was defined as
resistance to at least one antimicrobial in at least
three of the following antimicrobial groups: macro-
lides, quinolones, phenicol, and tetracycline
[17,18].
2.4. Data analysis
The number of laboratory-confirmed Campylobacter
infections was examined by quarter and stratified
by ambulatory and hospital settings separately for
Santa Rosa and Quetzaltenango. The total number
of diarrhea cases that were captured by the sur-
veillance system was also displayed per quarter.
Seasonality of Campylobacter infections was as-
sessed visually using time series graphs.
Annual crude rates for Campylobacter were cal-
culated. Population denominators were obtained
for the catchment area of the surveillance facili-
ties by healthcare setting for all ages and for
children <5 years, from 2000 through 2010 munici-
pality data from Guatemalas National Institute of
Statistics (INE) [13]. Population estimates for the
catchment areas in 2011 and 2012 were generated
by calculating the average change in municipality
population by age from 2009 to 2010, then assum-
ing that same change for 2011 and 2012.
Demographic and clinical characteristics of
case–patients treated at ambulatory and hospital
settings were compared using chi square tests. Fish-
ers exact tests were used when cell sizes had counts
of five or less. Demographic, geographic, healthcare
setting, and clinical differences were explored be-
tween patients who had antimicrobial susceptibility
data versus those who did not using chi square tests.
The proportion resistant was calculated for each of
the five tested antimicrobials for all Campylobacter
and the subset of C. jejuni. In addition, the differ-
ence was tested in the proportion of isolates that
were MDR from ambulatory versus hospital settings
using Fishers exact test.
2.5. Ethics
The surveillance protocol was approved by the
institutional review boards of the CDC and the
UVG, and approved by the Guatemalan MSPAS. Ver-
bal consent was requested of patients in order to
screen them for eligibility. Written, informed con-
sent was obtained from eligible patients who were
willing to participate. For patients <18 years of
Table 1 Number and crude rates of laboratory-confirmed Campylobacter cases captured at Santa Rosa and
Quetzaltenangoa surveillance sites by healthcare setting, January 1, 2008 – August 31, 2012.
Santa Rosa Quetzaltenango
Hospital Ambulatory Hospital Ambulatory
Number
of
cases
Crude rate
per 100,000
persons
Number
of cases
Crude
rate per
100,000
persons
Number
of cases
Crude rate
per 100,000
persons
Number
of
cases
Crude rate
per 100,000
persons
2008
<5 years 3 8.1 27 594.5 n/a n/a n/a n/a
All 3 1.2 28 92.5
2009
<5 years 6 16.1 34 745.5 n/a n/a n/a n/a
All 6 2.4 39 127.3
2010
<5 years 17 45.0 59 1288.8 3 5.4 6 48.3
All 17 6.6 67 215.8 3 0.8 7 8.5
2011
<5 years 0 0 46 1001.1 3 5.3 7 55.2
All 0 0 47 149.5 4 1.1 8 9.4
2012b
<5 years 4 25.0 28 910.7 5 13.2 16 185.5
All 4 4.1 32 150.8 5 1.9 16 27.3
a Surveillance in Quetzaltenango began in 2009.
b Rates account for partial year through August 31.
54 S.R. Benoit et al.age, parents or guardians were asked to provide
written, informed consent for the participation of
the patient. In addition, children aged 7 through
17 were asked for written, informed assent.
3. Results
During the five-year analysis period in Santa Rosa,
4327 patients met the case definition for diarrhea
and all but one consented to participate; 246
(6.3%) of 3929 (90.8%) stool specimens collected
yielded cultures positive for Campylobacter. Dur-
ing the three-year analysis period in Quetzaltenan-
go, 1336 patients met the case definition for
diarrhea and all but one consented to participate;
60 (5.0%) of 1208 (90.4%) stool specimens collected
yielded cultures positive for Campylobacter. No
seasonal pattern of disease was evident by visual
inspection of time series graphs. In the hospital
setting in Santa Rosa during 2008 through 2012,
the median crude annual incidence of Campylobac-
ter infections was 2.4 per 100,000 persons (range,
0–6.6) for all ages, and 16.1 per 100,000 persons
(range, 0–45.0) for children <5 years old (Table 1).
Median incidence in the ambulatory setting in San-
ta Rosa was 149.5 per 100,000 persons (range,
92.5–215.8) for all ages, and 910.7 per 100,000
persons (range, 594.5–1288.8) for children
<5 years old. In the ambulatory setting in Quetzal-
tenango during 2010 through 2012, the mediancrude annual rate was 9.4 per 100,000 persons
(range, 8.5–27.3) for all ages, and 55.2 per
100,000 persons (range, 48.3–185.5) for children
<5 years old. Of the 306 Campylobacter cases,
235 (76.8%) were C. jejuni (Table 2).
During the study period, the number of labora-
tory-confirmed Campylobacter infections and diar-
rhea cases captured by the surveillance system per
quarter varied, especially for Santa Rosa (Fig. 1a
and b). In Santa Rosa, the median proportion of
cases with a confirmed Campylobacter infection
per stool culture performed per quarter was 8.0%
(range, 0.4–17.1%) in the ambulatory setting and
4.1% (range, 0–11.1%) in the hospital setting. In
Quetzaltenango, the median proportion was 3.9%
(range, 0–13.5%) in the ambulatory setting and
5.0% (range, 0–15.8%) in the hospital setting. The
proportion of cases presenting to ambulatory
versus hospital settings was higher for both Santa
Rosa (86.6%) and Quetzaltenango (73.3%).
Over 40% of the Campylobacter infections oc-
curred in children <1 year of age, over 90% in chil-
dren <5 years (<50% of patients screened were
<5 years of age) (Table 2). More patients presenting
to the ambulatory versus hospital settings stated
that they had abdominal pain or cramping
(p = 0.0002). Over 40% of hospitalized versus
17.0% of ambulatory case–patients had an axillary
temperature of P38 C (p = 0.0002). A higher pro-
portion of hospitalized case–patients showed signs
Table 2 Characteristics of 306 laboratory-confirmed Campylobacter cases captured at Santa Rosa and Quetzaltenango
surveillance sites, stratified by healthcare setting, January 1, 2008 to August 31, 2012.
Total Ambulatory Hospital p value
N = 306 N = 257 N = 49
n (%) n (%) n (%)
Demographics
Age in years 0.15
<1 127 (41.5) 101 (39.3) 26 (53.1) a
1–4 155 (50.7) 135 (52.5) 20 (40.8)
5–18 11 (3.6) 11 (4.3) 0
19–50 6 (2.0) 5 (2.0) 1 (2.0)
>50 7 (2.3) 5 (2.0) 2 (4.1)
Male sex 171 (55.9) 148 (57.6) 23 (46.9) 0.17
History
Fever b 144 (53.3) 114 (51.4) 30 (62.5) 0.16
Bloody diarrhea 27 (8.8) 25 (9.7) 2 (4.1) 0.28 a
Abdominal pain/cramping b 145 (51.6) 136 (56.0) 9 (23.7) 0.0002
Clinical
Measured feverP 38 C b 58 (21.3) 38 (17.0) 20 (40.8) 0.0002
Sunken eyes 104 (34.0) 86 (33.5) 18 (36.7) 0.66
Oral mucosa <.0001
Somewhat dry 133 (43.5) 99 (38.5) 34 (69.4)
Very dry 19 (6.2) 13 (5.1) 6 (12.2)
Prolonged capillary refill b 13 (4.5) 11 (4.5) 2 (4.2) 0.92
Decreased skin turgor b 5 (1.7) 5 (2.0) 0 1.00a
Laboratory speciation 0.82
Campylobacter jejuni 235 (76.8) 198 (77.0) 37 (75.5)
Campylobacter sp. – unknown 71 (23.2) 59 (23.0) 12 (24.5)
Treatment
Admitted to intensive care unit b,c 4 (8.5)
Received intravenous fluids b,c 45 (94.0)
Received or prescribed oral rehydration solution b,d 152 (66.7)
Received or prescribed medication b,d 214 (93.9)
Azithromycin b 2 (0.9) 1 (2.7)
Chloramphenicol 0 0
Clindamycinb 0 0
Ciprofloxacin b 3 (1.3) 0
Doxycycline b 0 0
Erythromycin b 6 (3.2) 1 (2.7)
Levofloxacin**b 0 0
Metronidazole b 56 (25.0) 1 (2.7)
Trimethoprim sulfamethoxazole b 113 (50.5) 0
a Fishers exact test.
b Proportions based on non-missing data.
c Data only available in hospital setting.
d Data only available in ambulatory setting.
Burden of laboratory-confirmed Campylobacter infections 55of dehydration with somewhat or very dry oral
mucosa (p < 0.0001). Overall, 27 (8.8%) of the
case–patients reported bloody diarrhea.
Among hospitalized case–patients, 45 (94.0%)
received intravenous fluids; 4 (8.5%) were admit-
ted to the intensive care unit, all were 66 months
of age (Table 2). In the ambulatory setting, 152
patients (66.7%) received or were prescribed oral
rehydration solution. Of the 76 patients who didnot receive oral rehydration solution in the ambu-
latory setting, 64 (84.2%) were <5 years of age and
22 (34.4%) of them had sunken eyes, very dry
mucosa, delayed capillary refill, or decreased skin
turgor (data not shown). In the ambulatory
setting, most patients (75.5%) received or were
prescribed empiric therapy with metronidazole
or trimethoprim-sulfamethoxazole. No patients
died.
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Fig. 1a Number of laboratory-confirmed Campylobacter cases and diarrhea cases per quarter-year by patient-care
setting, Santa Rosa, Guatemala 2008–2012.
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Fig. 1b Number of laboratory-confirmed Campylobacter cases and diarrhea cases per quarter-year by patient-care
setting, Quetzaltenango, Guatemala 2009–2012.
56 S.R. Benoit et al.Antimicrobial susceptibility testing was per-
formed on 96 (31.4%) of the 306 laboratory-con-
firmed Campylobacter case isolates; there were
no demographic, geographic, healthcare setting,
or clinical differences between patients with and
patients without antimicrobial susceptibility data.Table 3 Number and percentage of Campylobacter isola
Quetzaltenango, Guatemala 2010–2011.
Antimicrobial class Antimicrobial All Cam
n (%)
Macrolide Erythromycin 12 (12.
Quinolones Ciprofloxacin 57 (59.
Nalidixic acid 62 (66.
Phenicol Chloramphenicol 11 (11.
Tetracycline Tetracycline 59 (61.Most specimens were C. jejuni (67.7%). Chloram-
phenicol had the lowest resistance rates while
the quinolones including nalidixic acid and cipro-
floxacin had the highest (Table 3). A total of 83
(86.4%) isolates were resistant to at least one anti-
microbial class and 12 (12.5%) were MDR (Table 4).tes resistant to antimicrobial agents, Santa Rosa and
pylobacter N = 96 Campylobacter jejuni N = 65
n (%)
5) 8 (12.3)
4) 42 (64.6)
7) 43 (68.3)
5) 7 (10.8)
5) 41 (63.1)
Table 4 Resistance patterns of Campylobacter isolates, Santa Rosa and Quetzaltenango, Guatemala 2010–2011.
Antimicrobial All Campylobacter N = 96 Campylobacter jejuni N = 65
n (%) n (%)
No resistance 13 (13.5) 10 (15.4)
Resistance to one antimicrobial class 32 (33.3) 18 (27.7)
Resistance to two antimicrobial classes 39 (40.6) 29 (44.6)
Resistance to three antimicrobial classes 10 (10.4) 7 (10.8)
Resistance to four antimicrobial classes 2 (2.1) 1 (1.5)
Burden of laboratory-confirmed Campylobacter infections 57There was no difference in the proportion of iso-
lates that were MDR in ambulatory versus hospital
settings (p = 0.44); 9 (75.0%) of the 12 macrolide-
resistant strains were MDR (data not shown).
4. Discussion
This study is the first large study to describe labo-
ratory-confirmed Campylobacter infections in Gua-
temala. In the ambulatory setting in Santa Rosa in
2010, crude annual incidence rates were as high
as 215.8 per 100,000 for all ages, and 1288.8 per
100,000 in children <5 years old. Campylobacter
primarily affected children <5 years of age, and
most patients presented to ambulatory care cen-
ters for treatment. Among isolates tested, the pro-
portion that was MDR was 12.5%.
In 2009 and 2010 the incidence of Campylobac-
ter infections in the United States reported by
FoodNet, which provides population-based esti-
mates of laboratory-confirmed infections com-
monly transmitted through food from 10 sites,
was 13.0 and 13.6 per 100,000 persons, respec-
tively, for all ages [19,20]. In the ambulatory set-
ting in Santa Rosa, crude incidence rates for all
ages in 2009 and 2010 were 10-fold higher than cor-
responding rates in the United States in 2009 and
16-fold higher for 2010. For the United States in
2010, FoodNet reported the incidence among chil-
dren <5 years old of 24.4 per 100,000 persons,
while in Santa Rosa during that year, this study
found an incidence of 1288.8 – over 50-fold great-
er [19]. The reported incidence rates in other parts
of the world varied, including 400 per 100,000 per-
sons in New Zealand (2003) [21], >120 per 100,000
in Australia (2005) [22], 44.1 per 100,000 in Europe
(2008) [23], and 30 per 100,000 in Canada (2004)
[24]. Rates from Quetzaltenango, Guatemala were
lower than Santa Rosa. It is important to note that
differences in the surveillance methodology may
impact incidence rates.
Quinolone-resistant Campylobacter strains have
been rising worldwide in the past two decades
[1,6]. The proportion of Campylobacter isolates
resistant to ciprofloxacin in the U.S. NationalAntimicrobial Resistance Monitoring System
(NARMS) in 2010 was 22.4% [17]. In Finland
(2003–2005), 45% of Campylobacter strains were
resistant to ciprofloxacin [18]. In SENTRY, a world-
wide laboratory surveillance network, 42.6% of
Campylobacter strains from 10 medical centers in
Latin America and 20 in Europe were resistant to
ciprofloxacin in 2003 [25]. The data from this
study, from April 2010 through December 2011,
show an even higher proportion of ciprofloxacin-
resistance of 59.4%. In addition, whereas 2.1% of
isolates reported in NARMS in 2010 were MDR, this
study found 12.5% of isolates from the Guatemalan
surveillance system to be MDR. Macrolide resis-
tance prevalence in the U.S. has been low (63%)
and steady over the past ten years. In Guatemala,
resistance prevalence was fourfold (12.5%) higher
compared with NARMS. Similar to Finnish data
[18], strains that were macrolide-resistant tended
to be MDR.
Although most Campylobacter infections are
self-limited and do not require antimicrobial ther-
apy, patients with severe infections, and those
who are immunocompromised or pregnant may re-
quire antimicrobial treatment. This studys data
suggest that resistant strains of Campylobacter
are prevalent, making antimicrobial agent selec-
tion difficult. In the sentinel sites in Guatemala,
>75% of patients in the ambulatory setting received
metronidazole or trimethoprim-sulfamethoxazole,
neither of which is effective against Campylobac-
ter. At the same time, one-third of patients in
the outpatient setting was not prescribed or did
not receive oral rehydration solution. Of those,
84.2% were children <5 years of age. One-third of
those patients <5 years of age who had not re-
ceived oral rehydration solution had at least one
sign of dehydration on physical exam. These find-
ings highlight the need to reemphasize the ade-
quate training and performance monitoring of
proper oral rehydration solution administration,
especially among young vulnerable populations.
Similar to the geographic variation in campylo-
bacteriosis in FoodNet sites in the U.S. [26], this
study also found large differences in the rates of
58 S.R. Benoit et al.Campylobacter infections and the number of pa-
tients presenting with diarrhea in Santa Rosa and
Quetzaltenango. The warm climate of Santa Rosa
likely contributes to the higher rate of diarrheal
disease in the department [27]. Differences in
healthcare seeking behaviors and hospital admit-
ting practices may also partially explain the differ-
ence. In the United States, campylobacteriosis is a
seasonal disease that peaks in the summer months
[26]. In Guatemala, a definitive seasonal pattern
was not observed, perhaps because temperatures
remain relatively stable throughout the year.
The findings of this study are subject to a num-
ber of limitations. Although the surveillance plat-
form includes most of the government facilities in
the populations studied, not all patients seek care
in these facilities and some do not seek care at all.
Therefore, the crude incidence rates are an under-
estimate of the true incidence of Campylobacter
disease. In addition, surveillance in the hospital
setting only includes patients who are admitted.
Thus, patients seen in the ED and then discharged
or transferred will not be included in this data,
again leading to underestimates in the rate calcula-
tions. The presence of Campylobacter in healthy
controls was not tested to determine what propor-
tion of the cases identified in this surveillance sys-
tem may have been asymptomatic carriers of
Campylobacter whose disease was caused by an-
other enteric pathogen. Finally, these data are
from the departments of Santa Rosa and Quetzal-
tenango and therefore may not be generalizable
to all of Guatemala. These data, however, are
the most comprehensive description of campylo-
bacteriosis in Guatemala and Central America in
the healthcare setting.
5. Conclusion
Campylobacter is a major cause of diarrhea in chil-
dren <5 years of age in Guatemala with disease
rates in the ambulatory setting significantly higher
than those of the United States. Consistent with
the epidemiology of Campylobacter elsewhere,
disease predominantly affected younger age
groups. Similar to FoodNet data from the United
States, rates varied substantially between sites,
but unlike FoodNet, no seasonal pattern was appar-
ent. Although treatment is normally supportive,
one-third of patients in the outpatient setting
was not prescribed or given oral rehydration ther-
apy and >75% were given an antimicrobial ineffec-
tive against Campylobacter. Quinolone-resistant
and MDR Campylobacter proportions were higher
in Guatemala than in other countries, potentiallycomplicating the treatment for immunocompro-
mised and pregnant patients or those with severe
disease. This study illustrates the capacity of a sen-
tinel healthcare facility-based surveillance system
to provide working estimates of the incidence of
an acute infectious disease. The next steps in
addressing the burden of campylobacteriosis in
Guatemala include the utilization of this platform
to identify risk factors for Campylobacter infection
through focused case–control studies; test inter-
ventions based on results of risk-factor studies,
aimed at reducing the burden of disease; identify
optimal treatment regimens for diarrhea in these
populations; and establish the further burden of
post-infectious sequelae of campylobacteriosis
and the economic cost of the illness.
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